4DMT Announces New Employment Inducement Grants
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced on January 17, 2026 that its compensation committee granted 23,600 Restricted Stock Units (RSUs) on January 13, 2026 to four new non-executive employees.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan, which the board approved in February 2025 under Nasdaq Rule 5635(c)(4) to permit equity grants that induce new hires to join the company.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
FDMT was down 0.79% while only one tracked peer (TECX) appeared in momentum scanners, moving up. Other peers showed mixed, mostly negative moves, suggesting stock-specific factors rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Corporate update | Positive | +8.1% | Outlined late-stage retinal milestones and cash runway through H2 2028. |
| Dec 17 | Clinical data update | Positive | -20.1% | Reported positive interim Phase 1 AEROW data for 4D-710 in cystic fibrosis. |
| Dec 12 | Inducement equity grants | Neutral | +1.0% | Granted 13,800 RSUs to new non-executive employees under inducement plan. |
| Dec 08 | Conference participation | Neutral | +3.5% | Announced presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 20 | Conference participation | Neutral | -4.3% | Planned fireside chat and meetings at Evercore Healthcare Conference. |
Recent news shows mixed price reactions, with one major positive clinical update selling off sharply while corporate and conference updates more often saw modest gains.
Over the last few months, FDMT has reported multiple corporate and clinical milestones. A January 2026 update outlined late-stage retinal program progress, increased Phase 3 enrollment targets, and cash of $514 million expected to fund operations into H2 2028, which coincided with an 8.07% gain. Positive interim Phase 1 data for 4D-710 in cystic fibrosis in December 2025 saw a 20.05% decline, contrasting with modestly positive reactions to conference participation and prior employment inducement grants. Today’s new RSU inducement grants fit into this pattern of ongoing equity-based hiring incentives.
Market Pulse Summary
This announcement details a routine equity compensation action: the grant of 23,600 RSUs to four new non-executive employees under 4DMT’s 2025 Employment Inducement Award Plan, adopted under Nasdaq Rule 5635(c)(4). It follows a similar inducement grant reported in December 2025, indicating ongoing hiring. Investors may contextualize this alongside recent milestones, including the January 2026 corporate update outlining late-stage retinal programs and a cash runway into H2 2028.
Key Terms
restricted stock units (rsus) financial
employment inducement award plan financial
nasdaq global market regulatory
AI-generated analysis. Not financial advice.
EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts: Media: Jenn Gordon dna Communications Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Strategic Finance Investor.Relations@4DMT.com
FAQ
How many RSUs did 4D Molecular Therapeutics (FDMT) grant on January 13, 2026?
Under which plan were the FDMT inducement RSUs granted?
Why did FDMT use Nasdaq Rule 5635(c)(4) for the January 2026 grants?
Were the FDMT RSU grants for executive or non-executive employees?
Does the January 2026 RSU announcement from FDMT include financial guidance or earnings figures?
When did 4D Molecular Therapeutics publicly announce the RSU grants for FDMT?
